Why the tumor microenvironment is key to the future of cancer therapy
Why the tumor microenvironment is key to the future of cancer therapy
Cancer research is evolving. Researchers are increasingly recognizing that therapeutic success depends not only on targeting cancer cells, but also on understanding the tumor microenvironment (TME) that surrounds and sustains them. Growing research interest in the TME is advancing understanding of its role in tumor progression, treatment response, and therapeutic resistance.
Discover peer-reviewed research and expert perspectives advancing understanding of the complex interactions shaping cancer development and treatment response.
Featured insights
Genomic approaches advancing glioblastoma science
Discover how single‑cell transcriptomics and functional genomics are revealing cellular heterogeneity and candidate drivers within the glioblastoma tumor microenvironment.
Unveiling cancer crosstalk across spatial and temporal scales
Learn how recent omics advancements are deepening insights into tumor progression—from tumorigenesis to metastatic dissemination.
Mapping the glioblastoma microenvironment through spatial transcriptomics
See how spatial transcriptomics reveals the role of cellular interactions in shaping the glioblastoma tumor microenvironment.
A new focus in cancer research
In the PLOS Biology article, TiME for a change: The tumor microenvironment as the missing piece in cancer therapeutics, Mo et al. argue that the TME is a critical but underutilized target in cancer therapy. Historically, cancer research and treatment strategies focused on genetic mutations within cancer cells, often overlooking the complex roles of the surrounding microenvironment. As a result, many experimental models lack the diversity and structure of real tumors, limiting their ability to predict clinical outcomes.
Recognizing and addressing this gap is now seen as essential for developing more effective, durable cancer therapies.
Beyond the cell: understanding stromal diversity
Addressing this gap means looking closely at the stroma, which is far from passive. Fibroblasts, immune cells, and the extracellular matrix (ECM) actively influence immune responses, metastasis, and how tumors adapt to treatment. Cancer-associated fibroblasts (CAFs) and other stromal components evolve alongside the tumor, shaping its progression and response to therapy. Recent studies reveal that stromal cells can both suppress and promote tumor growth, depending on context. This complexity underscores the need for models that capture the heterogeneity of the TME. Without this, therapies will continue to fall short, making stromal diversity a central challenge for future research.
Among the diverse stromal components, the ECM stands out for its dynamic influence on cancer progression
Recent research by Nazemi et al. demonstrates that the ECM can help breast cancer cells survive under amino acid starvation by promoting tyrosine catabolism. This metabolic adaptation reframes the ECM as more than structural support—it is a metabolic partner in cancer progression. By sustaining tumors under stress, the ECM highlights why therapies must disrupt these survival pathways to achieve lasting responses. Such findings open new avenues for research into metabolic vulnerabilities within the TME.
Join our life science research community
Connect with researchers and clinicians from around the world. Receive curated content and the latest journal updates spanning the life science disciplines - delivered straight to your inbox.
Turning insight into action: what is next for TME research?
Researchers are now developing innovative ways to model and manipulate the TME. Advances in 3D organoid systems, spatial mapping technologies, and immune-modulating therapies that treat the TME as a therapeutic target are all approaches that aim to recondition the microenvironment to support treatment rather than resistance.
Building on discoveries like those of Nazemi et al., the field is moving toward not only understanding how the microenvironment supports tumor survival, but also translating these insights into actionable strategies. By revealing specific metabolic dependencies, such as the ECM’s role in sustaining cancer cells under stress, this research helps identify new therapeutic targets within the TME. The next generation of cancer therapies will increasingly focus on disrupting these support systems, making the microenvironment less hospitable to cancer.
Uniting disciplines for personalized cancer care
Progress in this area depends on collaboration across disciplines—genetics, immunology, bioengineering, and computational science—working together to design therapies that target both cancer cells and their supportive niches. This integrated approach could also enable personalized strategies, guided by biomarkers that reflect the unique characteristics of each patient’s microenvironment. By aligning these efforts, researchers can move toward treatments that not only address the complexity of cancer but also improve outcomes for patients in a meaningful, sustainable way.
This commentary is based on TiME for a change: The tumor microenvironment as the missing piece in cancer therapeutics, published in PLOS Biology.
Discover the latest research
Dive deeper into the evolving field of tumor microenvironment research by exploring the latest articles from our life science journals.
Learn more about our life science journals
From molecular biology to ecosystem studies, our life science journals champion inclusive and high-impact research. By supporting transdisciplinary collaboration, we deepen our understanding of living systems and connect the global scientific community to drive meaningful advancements in the biological and life sciences.
